158 related articles for article (PubMed ID: 35626133)
1. A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma.
Dell'Anno I; Melani A; Martin SA; Barbarino M; Silvestri R; Cipollini M; Giordano A; Mutti L; Nicolini A; Luzzi L; Aiello R; Gemignani F; Landi S
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626133
[TBL] [Abstract][Full Text] [Related]
2. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I; Martin SA; Barbarino M; Melani A; Silvestri R; Bottaro M; Paolicchi E; Corrado A; Cipollini M; Melaiu O; Giordano A; Luzzi L; Gemignani F; Landi S
Invest New Drugs; 2021 Jun; 39(3):644-657. PubMed ID: 33300108
[TBL] [Abstract][Full Text] [Related]
3. Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling.
Dell'Anno I; Morani F; Patergnani S; Daga A; Pinton P; Giorgi C; Mutti L; Gemignani F; Landi S
Cancer Cell Int; 2024 Jun; 24(1):226. PubMed ID: 38951927
[TBL] [Abstract][Full Text] [Related]
4. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
5.
Dell'Anno I; Barbarino M; Barone E; Giordano A; Luzzi L; Bottaro M; Migliore L; Agostini S; Melani A; Melaiu O; Catalano C; Cipollini M; Silvestri R; Corrado A; Gemignani F; Landi S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659970
[TBL] [Abstract][Full Text] [Related]
6. Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of action.
Parvathaneni V; Chilamakuri R; Kulkarni NS; Wang X; Agarwal S; Gupta V
Life Sci; 2022 Oct; 306():120843. PubMed ID: 35908620
[TBL] [Abstract][Full Text] [Related]
7. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
8. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
9. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.
Kuramitsu Y; Tominaga W; Baron B; Tokuda K; Wang Y; Kitagawa T; Nakamura K
Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation.
Kulkarni NS; Vaidya B; Parvathaneni V; Bhanja D; Gupta V
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878257
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
Li Q; Wang W; Machino Y; Yamada T; Kita K; Oshima M; Sekido Y; Tsuchiya M; Suzuki Y; Nan-Ya K; Iida S; Nakamura K; Iwakiri S; Itoi K; Yano S
Cancer Sci; 2015 Jan; 106(1):102-7. PubMed ID: 25421609
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
14. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
15. A
Vincenzi F; Rotondo JC; Pasquini S; Di Virgilio F; Varani K; Tognon M
Front Oncol; 2021; 11():679285. PubMed ID: 34660262
[TBL] [Abstract][Full Text] [Related]
16. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.
Lee KA; Chae JI; Shim JH
J Biomed Sci; 2012 Jun; 19(1):60. PubMed ID: 22734486
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
19. The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
Oguh-Olayinka L; Agarwal V; Ranatunge D; Campbell A; Laufer S; Cawkwell L; Lind MJ
Pathol Oncol Res; 2020 Apr; 26(2):985-995. PubMed ID: 30941737
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
